Health

Gene Therapy Advances in Muscular Dystrophy

Updated 2026-05-14 11:20 UTC 1 source Positive

Regenxbio reported success in a clinical trial for its Duchenne muscular dystrophy gene therapy, setting the stage for FDA submission. CREATE Medicines secured significant funding to advance its CAR-T therapies.

Coverage timeline — 2 articles

STAT News

STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission

Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a submission to the FDA.

2026-05-14 11:00 UTC

STAT News

STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million

CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials.

2026-05-14 11:00 UTC